The ProPublica peptide safety story: what it got right and wrong
Investigative journalism serves a real function. So does knowing where the nuance lives.
TL;DR
- ProPublica's investigation raised legitimate concerns about the gray market for compounded peptides — those concerns are real.
- Where the reporting got thin: it didn't always separate licensed 503A pharmacies from unregulated online sellers.
- The practical takeaway: the channel matters more than the compound.
What it is
ProPublica is an investigative journalism outlet. Its 2025–2026 reporting examined the $1B+ market for compounded peptides dispensed outside traditional pharmaceutical channels. The investigation focused on quality-control failures, labeling inconsistencies, and the absence of FDA oversight at certain operations.
The core concern is legitimate. Some peptide sellers operate with no clinical oversight at all.
What it got right
The gray market is a real problem. Peptides sold online without a prescription — often labeled "research use only" — come with no quality verification, no physician involvement, and no accountability. ProPublica documented cases of mislabeled and contaminated products. The FDA has issued warning letters to dozens of such online sellers for exactly these reasons.
Where the context was thin
Licensed 503A compounding pharmacies (in plain English: state-regulated facilities that prepare patient-specific medications based on a valid prescription from a physician) operate under a very different framework. They are subject to state board of pharmacy inspection, USP (United States Pharmacopeia — the national standard-setting body for drug quality) standards, and mandatory physician authorization.
ProPublica's reporting did not always draw this line. Readers who concluded "all compounded peptides are dangerous" absorbed more than the evidence supported.
What the research says
A 2023 review in JAMA Internal Medicine found that compounding errors cluster at facilities operating outside standard oversight structures. Facilities operating under proper 503A frameworks showed a substantially lower adverse-event profile. The study examined safety reporting patterns, not efficacy.
What to know before considering it
No compounded medication is without risk. Quality varies by pharmacy, not just by compound. Before starting any peptide protocol, ask your clinician which pharmacy they work with, whether it is state-licensed and 503A-compliant, and what testing it performs for sterility and potency. Any peptide access through Halftime Health requires a licensed clinician evaluation.
The Halftime POV
ProPublica did a service by putting this conversation on the map. The gray market is real, and people deserve to understand the difference between "someone shipped me peptides from a website" and "a licensed physician evaluated me and a licensed pharmacy filled my prescription." Those are not the same. We built Halftime Health around the second model — because it's the only one that makes clinical sense.
Related reading:
- 503A vs. 503B pharmacies explained
- 503A pharmacy quality standards
- Category 1 vs. Category 2 peptides
- What are peptides?
FAQ
Q: What did ProPublica report about peptide safety? A: ProPublica investigated the compounded peptide market and raised concerns about oversight gaps, inconsistent testing, and gray-market sellers. The reporting was accurate about unregulated sources but did not consistently distinguish licensed 503A pharmacies from online sellers operating without clinical oversight.
Q: Are compounded peptides from licensed pharmacies safe? A: Compounded medications from state-licensed 503A pharmacies are subject to state board oversight and USP standards. The contamination and dosing errors ProPublica described are most associated with gray-market sources, not licensed clinical channels. Individual response varies; physician supervision is required.
Q: How do I verify a peptide source is legitimate? A: A legitimate source requires a valid prescription, a licensed clinician evaluation, and a state-licensed 503A compounding pharmacy. If peptides can be purchased online without a prescription, that source is not operating through a legal clinical channel.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- FDA Compounding Laws and Policies — FDA.gov
- Medication Errors in Compounding Pharmacies — JAMA Internal Medicine, 2023
Frequently asked questions
What did ProPublica report about peptide safety?
ProPublica investigated compounded peptides and raised concerns about oversight gaps at some compounding operations, inconsistent testing, and the gray market. The reporting was largely accurate about unregulated sources but did not always distinguish licensed 503A pharmacies from unregulated online sellers.
Are compounded peptides from licensed pharmacies safe?
Compounded medications from state-licensed 503A pharmacies are subject to state board oversight and USP standards. The contamination and dosing risks ProPublica described are most associated with gray-market sources. Individual response varies, and physician supervision is required.
How do I know if a peptide source is legitimate?
A legitimate source requires a valid prescription from a licensed clinician and uses a state-licensed 503A compounding pharmacy. If you can purchase peptides online without a prescription, that source is not operating through a legal clinical channel.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.